KLF5 and neoplasm: Results of the current study demonstrate a similar effect on tumor formation at 12 weeks of age in ApcMin/KRASV12 mice that were heterozygous for the Klf5 alleles, with the intestinal tumor burden reduced by more than 90% in the triple ApcMin/KRASV12/Klf5+/- transgenic mice when compared to the double ApcMin/KRASV12 transgenic mice (Fig. 1).